11th Apr 2014 07:59
LONDON (Alliance News) - Vectura Group PLC said Friday that it will begin a "pivotal" study in Europe later in 2014 for its product Favolir in the treatment of severe, uncontrolled asthma.
The company said that the study is part of its strategy for a broad development programme across Europe for Favolir, rather than taking a country-specific approach.
The company has recently met with the German regulator to discuss local development options for the treatment.
Shares in Vectura were trading down 9% at 130.31 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L